MedTrace Logo

Do Serotonin Reuptake Inhibitors (SSRIs) Affect Bone Mass in Adolescents

NCT02147184 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 287

Last updated 2023-06-28

Study results available
· View outcomes & findings →

Summary

Building on findings from animal studies, pediatric clinical trials, epidemiologic research in adults, and on preliminary findings from the investigators' laboratory in children and adolescents, this project aims to investigate whether selective serotonin reuptake inhibitors (SSRIs), a group of widely-used psychotropics, are associated with impaired bone mineralization in youths. Establishing such an association is a first step in a process that would eventually involve developing preventative interventions. Identifying genetic factors that place certain youths at higher risks for this side effect would ultimately allow clinicians to tailor treatment to the needs and vulnerabilities of each youth, moving the field closer towards individualized medicine.

Conditions

  • The Skeletal Effects of SSRIs

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Chadi A. Calarge

    lead OTHER

Principal Investigators

  • Chadi Calarge, MD · University of Iowa

Eligibility

Min Age
15 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02147184 on ClinicalTrials.gov